What is B. Riley’s Forecast for VKTX FY2025 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities researchers at B. Riley issued their FY2025 earnings per share (EPS) estimates for Viking Therapeutics in a note issued to investors on Thursday, October 23rd. B. Riley analyst W. Wood forecasts that the biotechnology company will earn ($2.77) per share for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.97) EPS, FY2026 earnings at ($3.72) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.03) EPS.

Several other research firms also recently weighed in on VKTX. Raymond James Financial dropped their target price on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a report on Thursday, July 24th. HC Wainwright reissued a “buy” rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Monday, September 29th. Citigroup increased their target price on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. JPMorgan Chase & Co. cut their price objective on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $85.62.

Viking Therapeutics Price Performance

Shares of VKTX stock opened at $34.42 on Monday. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.73. The firm has a market cap of $3.89 billion, a PE ratio of -16.24 and a beta of 0.64. The company has a 50-day moving average of $28.57 and a two-hundred day moving average of $28.83.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) earnings per share.

Institutional Investors Weigh In On Viking Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP lifted its position in Viking Therapeutics by 58.4% in the second quarter. Allworth Financial LP now owns 955 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 352 shares during the last quarter. Glass Jacobson Investment Advisors llc purchased a new stake in shares of Viking Therapeutics in the 2nd quarter valued at about $28,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Viking Therapeutics in the 2nd quarter valued at about $29,000. Quarry LP grew its stake in Viking Therapeutics by 1,621.4% during the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,135 shares during the last quarter. Finally, Avion Wealth increased its position in Viking Therapeutics by 1,157.0% during the third quarter. Avion Wealth now owns 1,521 shares of the biotechnology company’s stock worth $39,000 after buying an additional 1,400 shares during the period. 76.03% of the stock is currently owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.